呼吸指南

订阅

MedSci主页 / 所有栏目 / 呼吸指南

2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读

2018-12-10 《中国医学前沿杂志（电子版）》.2019,11(1):1-14.

慢性阻塞性肺病

慢性阻塞性肺疾病（ 慢阻肺）全球创议（global initiative for chronic obstructive lung disease，GOLD）2019年修订版于2018年11月7日发布，相较于GOLD 2018，GOLD 2019最重要的改变是在慢阻肺稳定期章节增加了慢阻肺初始药物治疗方案和随访期药物调整策略，并强调了血嗜酸粒细胞作为慢阻肺患者吸入激素获益的生物标志物。本文对新增加

中文标题：

2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读

发布机构：

发布日期：

2018-12-10

简要介绍：

慢性阻塞性肺疾病（ 慢阻肺）全球创议（global initiative for chronic obstructive lung disease，GOLD）2019年修订版于2018年11月7日发布，相较于GOLD 2018，GOLD 2019最重要的改变是在慢阻肺稳定期章节增加了慢阻肺初始药物治疗方案和随访期药物调整策略，并强调了血嗜酸粒细胞作为慢阻肺患者吸入激素获益的生物标志物。本文对新增加内容进行介绍和解读。 

作者： 北京大学第三医院呼吸与危重症医学科 陈亚红

拓展指南：与慢性阻塞性肺病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读)] GetToolGuiderByIdResponse(projectId=1, id=679141c0016e7a46, title=2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读, enTitle=, guiderFrom=《中国医学前沿杂志（电子版）》.2019,11(1):1-14., authorId=null, author=, summary=慢性阻塞性肺疾病（ 慢阻肺）全球创议（global initiative for chronic obstructive lung disease，GOLD）2019年修订版于2018年11月7日发布，相较于GOLD 2018，GOLD 2019最重要的改变是在慢阻肺稳定期章节增加了慢阻肺初始药物治疗方案和随访期药物调整策略，并强调了血嗜酸粒细胞作为慢阻肺患者吸入激素获益的生物标志物。本文对新增加, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Mon Dec 10 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>慢性阻塞性肺疾病（ 慢阻肺）全球创议（global initiative for chronic obstructive lung disease，GOLD）2019年修订版于2018年11月7日发布，相较于GOLD 2018，GOLD 2019最重要的改变是在慢阻肺稳定期章节增加了慢阻肺初始药物治疗方案和随访期药物调整策略，并强调了血嗜酸粒细胞作为慢阻肺患者吸入激素获益的生物标志物。本文对新增加内容进行介绍和解读。 </div> <div><br> </div>作者： 北京大学第三医院呼吸与危重症医学科 陈亚红 <div><br> </div> 拓展指南：<strong>与<font color=red>慢性阻塞性肺病</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=e111f1c001ae560b" title="2017 BC指南：慢性阻塞性肺病的诊断和管理" target=_blank>2017 BC指南：慢性阻塞性肺病的诊断和管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=252cc1c001160a88" title="慢性阻塞性肺病全球倡议慢性阻塞性肺病 指南（2013更新版）解读" target=_blank>慢性阻塞性肺病全球倡议慢性阻塞性肺病 指南（2013更新版）解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7b7dc1c00080e708" title="2011SATS 慢性阻塞性肺病诊治指南" target=_blank>2011SATS 慢性阻塞性肺病诊治指南</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E6%85%A2%E6%80%A7%E9%98%BB%E5%A1%9E%E6%80%A7%E8%82%BA%E7%97%85" target=_blank>有关慢性阻塞性肺病更多指南</a></ul>, tagList=[TagDto(tagId=7070, tagName=慢性阻塞性肺病)], categoryList=[CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=13461, appHits=1544, showAppHits=66, pcHits=8959, showPcHits=4245, likes=119, shares=78, comments=3, approvalStatus=1, publishedTime=Thu Dec 20 22:17:50 CST 2018, publishedTimeString=2018-12-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Dec 20 22:17:50 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 07:22:46 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读)])
2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=962365, encodeId=ff6096236536, content=太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/ae26ed5d9e954afc8498d82504217e3f/29fc481de32d44739419d58235d7f495.jpg, createdBy=12d85257694, createdName=147f6117m19暂无昵称, createdTime=Sun May 02 21:39:20 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915600, encodeId=586291560047, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780f5072997, createdName=14598acfm71暂无昵称, createdTime=Mon Jan 11 15:59:00 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358078, encodeId=333f3580e8ee, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e82e2530546, createdName=124fe990m59暂无昵称, createdTime=Mon Jan 14 07:25:31 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2021-05-02 147f6117m19暂无昵称

    太赞了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=962365, encodeId=ff6096236536, content=太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/ae26ed5d9e954afc8498d82504217e3f/29fc481de32d44739419d58235d7f495.jpg, createdBy=12d85257694, createdName=147f6117m19暂无昵称, createdTime=Sun May 02 21:39:20 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915600, encodeId=586291560047, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780f5072997, createdName=14598acfm71暂无昵称, createdTime=Mon Jan 11 15:59:00 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358078, encodeId=333f3580e8ee, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e82e2530546, createdName=124fe990m59暂无昵称, createdTime=Mon Jan 14 07:25:31 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2021-01-11 14598acfm71暂无昵称

    感谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=962365, encodeId=ff6096236536, content=太赞了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211004/ae26ed5d9e954afc8498d82504217e3f/29fc481de32d44739419d58235d7f495.jpg, createdBy=12d85257694, createdName=147f6117m19暂无昵称, createdTime=Sun May 02 21:39:20 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=915600, encodeId=586291560047, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=780f5072997, createdName=14598acfm71暂无昵称, createdTime=Mon Jan 11 15:59:00 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358078, encodeId=333f3580e8ee, content=内容丰富, beContent=null, objectType=guider, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e82e2530546, createdName=124fe990m59暂无昵称, createdTime=Mon Jan 14 07:25:31 CST 2019, time=2019-01-14, status=1, ipAttribution=)]
    2019-01-14 124fe990m59暂无昵称

    内容丰富

    0

相关指南

2018 瑞士建议：稳定型COPD和急性加重型COPD的诊断，预防和治疗

国外呼吸科专家组（统称） · 2018-08-23

2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读

暂未更新 · 2017-12-26

2018 GOLD慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略

慢性阻塞性肺疾病全球倡议(GOLD,The Global Initiative for Chronic Obstructive Lung Disease) · 2017-11-01

2017 GOLD慢性阻塞性肺疾病全球倡议：COPD诊断、治疗与预防全球策略

暂未更新 · 2016-11-10

慢性阻塞性肺病全球倡议慢性阻塞性肺病 指南（2013更新版）解读

暂未更新 · 2016-04-20